Discovery and development of extreme selective inhibitors of the ITD and D835Y 
mutant FLT3 kinases

Baska, Ferenc; Sipos, Anna; Örfi, Zoltán; Nemes, Zoltan; Dobos, Judit; Szantai-Kis, Csaba; Szabo, Eszter; Szenasi, Gabor; Dezsi, Laszlo; Hamar, Peter; Cserepes, Mihaly T.; Tovari, Jozsef; Garamvolgyi, Rita; Kreko, Marcell; Orfi, Laszlo

doi:10.1016/j.ejmech.2019.111710

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

MPS-Authors

/persons/resource/persons146877

Örfi, Zoltán
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Baska, F., Sipos, A., Örfi, Z., Nemes, Z., Dobos, J., Szantai-Kis, C., Szabo, E., Szenasi, G., Dezsi, L., Hamar, P., Cserepes, M. T., Tovari, J., Garamvolgyi, R., Kreko, M., & Orfi, L. (2019). Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 184:. doi:10.1016/j.ejmech.2019.111710.

引用: https://hdl.handle.net/21.11116/0000-0005-73BF-3

要旨

Aberrant activation of FMS-like tyrosine receptor kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML) in 20-30% of patients. In this study we identified a highly selective (phenylethenyl)quinazoline compound family as novel potent inhibitors of the FLT3-ITD and FLT3-D835Y kinases. Their prominent effects were confirmed by biochemical and cellular proliferation assays followed by mice xenograft studies. Our modelling experiments and the chemical structures of the compounds predict the possibility of covalent inhibition. The most effective compounds triggered apoptosis in FLT3-ITD AML cells but had either weak or no effect in FLT3-independent leukemic and non-leukemic cell lines. Our results strongly suggest that our compounds may become therapeutics in relapsing and refractory AML disease harboring various ITD and tyrosine kinase domain mutations, by their ability to overcome drug resistance. (C) 2019 Elsevier Masson SAS. All rights reserved.